Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

被引：39
|
作者：
Janjigian, Y. Y. [1 ]
Al-Batran, S-E. [2 ]
Wainberg, Z. A. [3 ]
Van Cutsem, E. [4 ,5 ]
Molena, D. [6 ]
Muro, K. [7 ]
Hyung, W. J. [8 ]
Wyrwicz, L. S. [9 ]
Oh, D. Y. [10 ,11 ]
Omori, T. [12 ]
Moehler, M. [13 ]
Garrido, M. [14 ,15 ]
Oliveira, S. Cunha Sousa [16 ]
Liberman, M. [17 ]
Oliden, V. Castro [18 ]
Bilici, M. [19 ]
Kurland, J. F. [20 ]
Xynos, I. [21 ]
Mann, H. [21 ]
Tabernero, J. [22 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY USA
[2] Univ Canc Ctr, Inst Clin Canc Res, Krankenhaus Nordwest, Frankfurt, Germany
[3] UCLA, David Geffen Sch Med, Dept Gastrointestinal Med Oncol, Los Angeles, CA USA
[4] Univ Hosp Leuven, Dept Gastroenterol Digest Oncol, Leuven, Belgium
[5] Katholieke Univ Leuven, Leuven, Belgium
[6] Mem Sloan Kettering Canc Ctr, Div Thorac Surg, New York, NY USA
[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[8] Yonsei Univ, Dept Surg, Coll Med, Seoul, South Korea
[9] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland
[10] Seoul Natl Univ Hosp, Div Med Oncol, Dept Internal Med, Seoul, South Korea
[11] Seoul Natl Univ, Canc Res Inst, Coll Med, Seoul, South Korea
[12] Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan
[13] Johannes Gutenberg Univ Clin, Res Ctr Immunotherapy FZI, Mainz, Germany
[14] SAGA Clin Trial Ctr, Hemato Oncol Dept, Santiago, Chile
[15] Univ Mayor, Santiago, Chile
[16] Clin Res Ctr, Northern Riograndense League Canc, Clin Oncol, Natal, RN, Brazil
[17] Ctr Hosp Univ Montreal Ctr Rech CHUM, Dept Surg, Div Thorac Surg, Montreal, PQ, Canada
[18] Natl Inst Neoplast Dis INEN, Med Oncol Dept, Lima, Peru
[19] Ataturk Univ, Dept Med Oncol, Fac Med, Erzurum, Turkiye
[20] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA
[21] AstraZeneca, Oncol R&D, Late Stage Dev, Cambridge, England
[22] UVic UCC, Vall Hebron Hosp Campus & Inst Oncol VHIO, Dept Med Oncol, IOB Quiron, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.074
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA73
引用
收藏
页码：S1315 / S1316
页数：2
相关论文
共 50 条
  • [31] Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Lordick, F.
    Luber, B.
    Lorenzen, S.
    Hegewisch-Becker, S.
    Folprecht, G.
    Woell, E.
    Decker, T.
    Endlicher, E.
    Roethling, N.
    Schuster, T.
    Keller, G.
    Fend, F.
    Peschel, C.
    BRITISH JOURNAL OF CANCER, 2010, 102 (03) : 500 - 505
  • [32] Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    F Lordick
    B Luber
    S Lorenzen
    S Hegewisch-Becker
    G Folprecht
    E Wöll
    T Decker
    E Endlicher
    N Röthling
    T Schuster
    G Keller
    F Fend
    C Peschel
    British Journal of Cancer, 2010, 102 : 500 - 505
  • [33] Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study
    Pauligk, Claudia
    Meiler, Johannes
    Hofheinz, Ralf Dieter
    Kopp, Hans-Georg
    Mayer, Frank
    Schmalenberg, Harald
    Luley, Kim
    Haag, Georg Martin
    Schmiegel, Wolff H.
    Homann, Nils
    Probst, Stephan
    Koenigsmann, Michael
    Prasnikar, Nicole
    Trojan, Jorg
    Egger, Matthias
    Mahlberg, Rolf
    Heike, Michael
    Tannapfel, Andrea
    Jaeger, Elke
    Al-Batran, Salah-Eddin
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Luber, Birgit
    Deplazes, Joelle
    Keller, Gisela
    Walch, Axel
    Rauser, Sandra
    Eichmann, Martin
    Langer, Rupert
    Hoefler, Heinz
    Hegewisch-Becker, Susanna
    Folprecht, Gunnar
    Woell, Ewald
    Decker, Thomas
    Endlicher, Esther
    Lorenzen, Sylvie
    Fend, Falko
    Peschel, Christian
    Lordick, Florian
    BMC CANCER, 2011, 11
  • [35] Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
    Birgit Luber
    Joëlle Deplazes
    Gisela Keller
    Axel Walch
    Sandra Rauser
    Martin Eichmann
    Rupert Langer
    Heinz Höfler
    Susanna Hegewisch-Becker
    Gunnar Folprecht
    Ewald Wöll
    Thomas Decker
    Esther Endlicher
    Sylvie Lorenzen
    Falko Fend
    Christian Peschel
    Florian Lordick
    BMC Cancer, 11
  • [36] Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study)
    Zaanan, Aziz
    Samalin, Emmanuelle
    Aparicio, Thomas
    Bouche, Olivier
    Laurent-Puig, Pierre
    Manfredi, Sylvain
    Michel, Pierre
    Monterymardi, Carole
    Moreau, Marie
    Rougier, Philippe
    Tougeron, David
    Taieb, Julien
    Louvet, Christophe
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (04) : 408 - 410
  • [37] Phase III trial of docetaxel cisplatin 5-fluorouracil induction chemotherapy for resectable oral cancer suggests favorable pathological response as a surrogate endpoint for good therapeutic outcome
    Ju, Wu-tong
    Liu, Ying
    Wang, Li-zhen
    Li, Jiang
    Ren, Guo-xing
    Sun, Jian
    Tu, Wen-yong
    Hu, Yong-jie
    Ji, Tong
    Yang, Wen-jun
    Li, Jun
    He, Yue
    Wang, Yan-an
    Zhang, Chen-ping
    Zhong, Lai-ping
    Zhang, Zhi-yuan
    CANCER COMMUNICATIONS, 2021, 41 (03) : 279 - 283
  • [38] Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel in gastric cancer with severe peritoneal metastasis (JCOG1108/WJOG7312G).
    Yamaguchi, Kensei
    Nakajima, Takako Eguchi
    Boku, Narikazu
    Hyodo, Ichinosuke
    Mizusawa, Junki
    Hara, Hiroki
    Nishina, Tomohiro
    Sakamoto, Takeshi
    Shitara, Kohei
    Shinozaki, Katsunori
    Katayama, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [39] A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with resectable locally advanced gastric cancer: An interim efficacy report.
    Kim, Hyung-Don
    Ryu, Min-Hee
    Park, Young Soo
    Lee, Jong Seok
    Kang, Yoon-Koo
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 408 - 408
  • [40] SUNITINIB PLUS 5-FLUOROURACIL, LEUCOVORIN AND OXALIPLATIN (MFOLFOX6) VS. BEVACIZUMAB PLUS MFOLFOX6 IN FRST-LINE METASTATIC COLORECTAL CANCER (MCRC) - INTERIM RESULTS OF A RANDOMIZED, PHASE IIB STUDY
    Hecht, J.
    Yoshino, T.
    Mitchell, E.
    Dees, M.
    Kroening, H.
    Patel, R.
    Welslau, M.
    Dakhil, S.
    Yamazaki, K.
    Maneval, Chow E.
    Kretzschmar, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 15 - 15
12345